Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SporTRIA: Triamcinolone acetonide excretion kinetics in athletes
NCT04574232Unknown
- Sponsor
- CHRU de Nancy - Hôpital Central
- Start
- Jan 2023
- Primary completion
- Dec 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Open-label, single-arm trial of triamcinolone acetonide in Knee joint disorder (KJD), sponsored by CHRU de Nancy - Hôpital Central. Primary endpoint: Excretion profile of triamcinolone acetonide in urine at 35 days. Status: unknown.
02
Drugs
triamcinolone acetonide
03
Conditions
Knee joint disorder (KJD)
Beyond the preview
Go deeper on NCT04574232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04574232.